phase ii trial design
3 Fatal Gaps In Prescription Weight Loss Trials
In 2024, three fatal gaps were identified in prescription weight loss trials: they omit lean-mass endpoints, lack trial designs that capture muscle repair, and fail to translate mouse findings to patients. Addressing these gaps ensures that GLP-1 drugs are judged on true body-composition benefits, not just fat loss. Medical Disclaimer: